From: Antiproliferative effect of the jararhagin toxin on B16F10 murine melanoma
 | Control | 0.8 μM JARA | 0.2 μM JARI |
---|---|---|---|
Total n° mice | 10 | 10 | 10 |
Dorsal tumor | Â | Â | Â |
Incidence | 10/10 (100%) | 8/10 (80%) | 10/10 (100%) |
Mean volume (mm3) | 17.8 ± 4.5 | 5.8 ± 1.2 (p = 0.01) | 3.4 ± 0.7* (p = 0.0016) |
Metastasis | Â | Â | Â |
Nodules Incidence | 10/10 (100%) | 4/10 (40%)* (p = 0.0108) | 2/10 (20%)* (p = 0.0007) |
Mean volume (mm3) | 42.10 ± 23.20 | 2.78 ± 6.10* (p < 0.0001) | 1.31 ± 2.90* (p < 0.0001) |
Multiplicity | 5.8 ± 1.22 | 0.70 ± 1.05* (p < 0.0001) | 0.40 0.96* (p = 0.0001) |
Metastases distribution | Â | Â | Â |
1- Lung | 42 (72.4%) | 02 (28.5%) | 03 (75%) |
2- Liver | 01 (1.7%) | 01 (14.2%) | 0 |
3- Spleen | 01 (1.7%) | 01 (14.2%) | 0 |
4- Kidney | 05 (8.6%) | 0 | 0 |
5- Lymph nodes | 09 (15.5%) | 03 (42.8%) | 01 (25%) |
Total n° nodules | 58 | 07**p < 0.01 | 04***p < 0.001 |
87.2% | 93.1% |